NCT05207995View on ClinicalTrials.gov

The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 26, 2023

Study Completion Date

December 26, 2023

Conditions
Diabetes Mellitus
Interventions
BIOLOGICAL

Autologous tolerogenic dendritic cells

Autologous tolerogenic dendritic cells treated with Vitamin-D3, co-cultivated with mesenchymal stem cell and primed peptides (MSC-tolDC) injected subcutaneous.

OTHER

Standard treatment according to the clinical protocols

Standard treatment of type 1 diabetes mellitus according to the clinical protocols

Trial Locations (1)

220000

"Healthcare institution Minsk City Clinical Endocrinology Center", Minsk

All Listed Sponsors
collaborator

Belarusian State Medical University

OTHER

lead

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

OTHER_GOV